IS6957A - Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim - Google Patents
Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeimInfo
- Publication number
- IS6957A IS6957A IS6957A IS6957A IS6957A IS 6957 A IS6957 A IS 6957A IS 6957 A IS6957 A IS 6957A IS 6957 A IS6957 A IS 6957A IS 6957 A IS6957 A IS 6957A
- Authority
- IS
- Iceland
- Prior art keywords
- triacetetracyclo
- tatrate
- pentaene
- hexadecene
- salts
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29086101P | 2001-05-14 | 2001-05-14 | |
PCT/IB2002/001437 WO2002092089A1 (en) | 2001-05-14 | 2002-04-26 | Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
IS6957A true IS6957A (is) | 2003-09-15 |
IS2217B IS2217B (is) | 2007-03-15 |
Family
ID=23117845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6957A IS2217B (is) | 2001-05-14 | 2003-09-15 | Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,8,-pentaeni. |
Country Status (48)
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69839131T3 (de) * | 1997-12-31 | 2015-05-07 | Pfizer Products Inc. | Arylkondensierte azapolycyclische derivate |
JP2005528330A (ja) * | 2001-11-30 | 2005-09-22 | ファイザー・プロダクツ・インク | 5,7,14−トリアザテトラシクロ[10.3.1.02,11.04,9]−ヘキサデカ−2(11)3,5,7,9−ペンタエンの医薬組成物 |
WO2004103372A1 (en) * | 2003-05-20 | 2004-12-02 | Pfizer Products Inc. | Pharmaceutical compositions of varenicline |
WO2005061519A1 (en) * | 2003-12-19 | 2005-07-07 | Takeda San Diego, Inc. | Kinase inhibitors |
JP2007533753A (ja) * | 2004-04-23 | 2007-11-22 | タケダ サン ディエゴ インコーポレイテッド | インドール誘導体及びキナーゼ阻害剤としてのその使用 |
JP2008505075A (ja) * | 2004-06-30 | 2008-02-21 | イーライ リリー アンド カンパニー | 1−(インドール−6−カルボニル−d−フェニルグリシニル)−4−(1−メチルピペリジン−4−イル)ピペラジンd−酒石酸塩 |
JP2008510734A (ja) * | 2004-08-18 | 2008-04-10 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
WO2006040680A1 (en) * | 2004-10-15 | 2006-04-20 | Pfizer Products Inc. | Compositions and methods for intranasal, buccal, sublingual and pulmonary delivery of varenicline |
EP1812439B2 (en) * | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2006090236A1 (en) * | 2005-02-24 | 2006-08-31 | Pfizer Products Inc. | Preparation of high purity substituted quinoxaline |
US20110086086A1 (en) * | 2005-07-26 | 2011-04-14 | Pfizer Inc | Transdermal system for varenicline |
US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
MX2007012605A (es) * | 2006-02-21 | 2008-01-11 | Teva Pharma | Formas cristalinas novedosas de armodafinil y preparacion de ellas. |
EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
US20100120717A1 (en) | 2006-10-09 | 2010-05-13 | Brown Jason W | Kinase inhibitors |
MX2009005043A (es) * | 2006-11-09 | 2009-05-25 | Pfizer Prod Inc | Polimorfos de intermedios nicotinicos. |
US20090062257A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched varenicline |
US20090105346A1 (en) * | 2007-10-02 | 2009-04-23 | Alexandr Jegorov | Novel crystalline forms of armodafinil and preparation thereof |
US20090215787A1 (en) * | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
US8440825B2 (en) | 2008-03-06 | 2013-05-14 | Medichem S.A. | Fumaric acid salt of varenicline |
EP2262780A4 (en) * | 2008-03-06 | 2012-01-25 | Reddys Lab Ltd Dr | TARTRATE OF VARENICLINE AMORPHOUS |
US9463190B2 (en) * | 2008-03-31 | 2016-10-11 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
EP2268639A2 (en) * | 2008-05-22 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
WO2009155403A2 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation of varenicline and intermediates thereof |
US20100010221A1 (en) * | 2008-07-10 | 2010-01-14 | Revital Lifshitz-Liron | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
WO2010023561A1 (en) * | 2008-09-01 | 2010-03-04 | Actavis Group Ptc Ehf | Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof |
WO2010143070A2 (en) | 2009-06-10 | 2010-12-16 | Actavis Group Ptc Ehf | Amorphous varenicline tartrate co-precipitates |
WO2010151524A1 (en) * | 2009-06-22 | 2010-12-29 | Teva Pharmaceutical Industries Ltd | Solid states forms of varenicline salts and processes for preparation thereof |
AU2011225747A1 (en) | 2010-03-09 | 2012-09-27 | Actavis Group Ptc Ehf | Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
CN104334561B (zh) | 2012-04-13 | 2016-06-22 | 连云港金康和信药业有限公司 | 化合物jk12a及其制备 |
KR101663550B1 (ko) * | 2014-06-11 | 2016-10-07 | 조선대학교산학협력단 | 주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품 |
KR101724301B1 (ko) | 2016-11-22 | 2017-04-10 | 주식회사 한서켐 | 바레니클린 살리실산염의 i형 결정 및 그 제조방법 |
WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
EP4142734A1 (en) | 2020-04-28 | 2023-03-08 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
EP4389748A2 (en) | 2021-08-20 | 2024-06-26 | Viwit Pharmaceutical Co., Ltd. | Nitrosamine impurity, varenicline pharmaceutical composition capable of reducing generation of nitrosamine impurities and preparation and use thereof |
KR20230068877A (ko) | 2021-11-11 | 2023-05-18 | 주식회사 아울바이오 | 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물 |
CN113980020B (zh) * | 2021-11-22 | 2023-05-09 | 浙江车头制药股份有限公司 | 一种酒石酸伐尼克兰晶型的制备方法 |
WO2023275413A2 (en) | 2021-12-23 | 2023-01-05 | Medichem, S.A. | Solid pharmaceutical formulations of varenicline |
EP4241775A1 (en) | 2022-03-11 | 2023-09-13 | Par Pharmaceutical, Inc. | Tablet comprising varenicline and process of preparation thereof |
US11602537B2 (en) | 2022-03-11 | 2023-03-14 | Par Pharmaceutical, Inc. | Varenicline compound and process of manufacture thereof |
WO2024095172A1 (en) | 2022-11-04 | 2024-05-10 | Pfizer Inc. | Prodrugs of varenicline and compounds containing vulnerable amines |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3471503A (en) | 1967-05-05 | 1969-10-07 | Mcneilab Inc | 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols |
DE69839131T3 (de) * | 1997-12-31 | 2015-05-07 | Pfizer Products Inc. | Arylkondensierte azapolycyclische derivate |
IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
YU34501A (sh) * | 2000-05-26 | 2003-10-31 | Pfizer Products Inc. | Postupak reaktivne kristalizacije radi povećanja veličine čestica |
-
2002
- 2002-04-26 PL PL366551A patent/PL214876B1/pl unknown
- 2002-04-26 CN CNB028099125A patent/CN100370987C/zh not_active Expired - Lifetime
- 2002-04-26 OA OA1200300289A patent/OA12599A/en unknown
- 2002-04-26 IL IL15793302A patent/IL157933A0/xx unknown
- 2002-04-26 SI SI200230189T patent/SI1392307T1/sl unknown
- 2002-04-26 JP JP2002589006A patent/JP3779682B2/ja not_active Expired - Lifetime
- 2002-04-26 AT AT02722625T patent/ATE302607T1/de active
- 2002-04-26 AU AU2002253482A patent/AU2002253482B2/en not_active Expired
- 2002-04-26 SK SK1336-2003A patent/SK287170B6/sk not_active IP Right Cessation
- 2002-04-26 DK DK02722625T patent/DK1392307T3/da active
- 2002-04-26 HU HU0304088A patent/HU229867B1/hu unknown
- 2002-04-26 EP EP02722625A patent/EP1392307B1/en not_active Expired - Lifetime
- 2002-04-26 NZ NZ528210A patent/NZ528210A/en not_active IP Right Cessation
- 2002-04-26 EA EA200301121A patent/EA005528B1/ru active Protection Beyond IP Right Term
- 2002-04-26 WO PCT/IB2002/001437 patent/WO2002092089A1/en active IP Right Grant
- 2002-04-26 RS YUP-867/03A patent/RS50814B/sr unknown
- 2002-04-26 KR KR1020037014754A patent/KR100551184B1/ko active IP Right Review Request
- 2002-04-26 BR BR0209605-6A patent/BR0209605A/pt not_active IP Right Cessation
- 2002-04-26 UA UA20031110266A patent/UA73422C2/uk unknown
- 2002-04-26 PT PT02722625T patent/PT1392307E/pt unknown
- 2002-04-26 ME MEP-2008-717A patent/ME00466B/me unknown
- 2002-04-26 CZ CZ2003-2916A patent/CZ304763B6/cs not_active IP Right Cessation
- 2002-04-26 GE GE5341A patent/GEP20053712B/en unknown
- 2002-04-26 EE EEP200300556A patent/EE05441B1/xx unknown
- 2002-04-26 DE DE60205742T patent/DE60205742T2/de not_active Expired - Lifetime
- 2002-04-26 CA CA002447405A patent/CA2447405C/en not_active Expired - Lifetime
- 2002-04-26 MX MXPA03010364A patent/MXPA03010364A/es active IP Right Grant
- 2002-04-26 ES ES02722625T patent/ES2246396T3/es not_active Expired - Lifetime
- 2002-05-06 US US10/139,730 patent/US6890927B2/en not_active Expired - Lifetime
- 2002-05-06 DO DO2002000392A patent/DOP2002000392A/es unknown
- 2002-05-09 AP APAP/P/2002/002523A patent/AP1473A/en active
- 2002-05-10 PE PE2002000391A patent/PE20021065A1/es active IP Right Grant
- 2002-05-10 GT GT200200084A patent/GT200200084A/es unknown
- 2002-05-10 MY MYPI20021696A patent/MY127807A/en unknown
- 2002-05-13 TW TW091109919A patent/TWI262078B/zh not_active IP Right Cessation
- 2002-05-13 AR ARP020101734A patent/AR033635A1/es active IP Right Grant
- 2002-05-13 EG EG20020483A patent/EG24228A/xx active
- 2002-05-14 PA PA20028545101A patent/PA8545101A1/es unknown
-
2003
- 2003-07-08 TN TNPCT/IB2002/001437A patent/TNSN03113A1/fr unknown
- 2003-09-15 IS IS6957A patent/IS2217B/is unknown
- 2003-09-15 IL IL157933A patent/IL157933A/en active IP Right Grant
- 2003-09-16 ZA ZA200307235A patent/ZA200307235B/en unknown
- 2003-09-22 CR CR7080A patent/CR7080A/es not_active Application Discontinuation
- 2003-11-10 HR HR20030910A patent/HRP20030910B1/xx not_active IP Right Cessation
- 2003-11-10 MA MA27389A patent/MA27020A1/fr unknown
- 2003-11-11 BG BG108343A patent/BG66408B1/bg unknown
- 2003-11-13 NO NO20035036A patent/NO326148B1/no not_active IP Right Cessation
- 2003-11-14 EC EC2003004850A patent/ECSP034850A/es unknown
- 2003-11-14 EC EC2003004849A patent/ECSP034849A/es unknown
-
2004
- 2004-07-28 HK HK04105577A patent/HK1062645A1/xx not_active IP Right Cessation
-
2005
- 2005-02-28 US US11/069,724 patent/US7265119B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS6957A (is) | Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim | |
NO2023030I1 (no) | Apixaban and pharmaceutical acceptable salts thereof | |
NO20033566L (no) | Acylerte 6,7,8,9-tetrehydro-5H-benzocykloheptenyl-aminer og deres anvendelse som farmasöytiske midler | |
NO20024175L (no) | Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene | |
FI20011478A0 (fi) | Farmaseuttinen koostumus | |
NO20042739L (no) | Farmasoytiske sammensetninger av 5,6,14-triazatetracyklo(10.3.1.0(2,11).0(4,9))-heksadeca-2(11)3,5,7,9-pentan | |
NO20033556L (no) | Farmasöytiske formuleringer | |
DE60203581D1 (de) | Alfa-beta Titanlegierung | |
NO20035298D0 (no) | CDK-inhiberende pyrimider, deres fremstilling og deres anvendelse som legemidler | |
DE60234409D1 (de) | Säuregenerator, Sulfonsäure, Sulfonsäurederivate und strahlungsempfindliche Zusammensetzung | |
NO20040125L (no) | Enterale formuleringer | |
EE200300416A (et) | Ravimvorm | |
NO20042635L (no) | 5-Sulfanyl-ñH-1,2,4-triazol-derivater og deres anvendelse som medisin | |
DK1417206T3 (da) | Hidtil ukendte 2H-pyridazin-3-on-derivater, farmaceutiske præparater indeholdende det samme, og en fremgangsmåde til fremstilling af den aktive bestanddel | |
DE60209929D1 (de) | Succinate des 5,8,14-triazatetracycloä10.3.1.0 2,11 .0 4,9 ü-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen | |
IS7051A (is) | Lyfjasamsetningar | |
IS6956A (is) | Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því | |
FI20022128A0 (fi) | Farmaseuttinen koostumus | |
DK1373232T3 (da) | Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner | |
DK1429753T3 (da) | Farmaceutisk sammensætning omfattende gamma-butyrobetain | |
EE200300465A (et) | Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid | |
NO20031369L (no) | Kalium-kanal interagerende forbindelser, og anvendelser derav | |
DK1235809T3 (da) | Substituerede 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazociner og deres anvendelse som lægemidler | |
DE50310743D1 (de) | Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat | |
IS7131A (is) | Nýjar 2,4-díamínóþíasól afleiður |